Tranzyme Pharma Announces Top-Line Results of TZP-102 Phase 2b Trial

Tranzyme Pharma Announces Top-Line Results of TZP-102 Phase 2b Trial

      Preliminary Analysis Indicates Trial Did Not Meet Primary Endpoint

             Tranzyme to Host Conference Call Today at 8:00 am ET

RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Tranzyme
Pharma (Nasdaq:TZYM), today announced top-line results of the preliminary
analysis of the first of two Phase 2b trials assessing the safety and efficacy
of its oral ghrelin agonist, TZP-102 in diabetic patients with gastroparesis.
The results, which evaluated patients who were given a single daily dose of 10
mg of TZP-102, 20 mg of TZP-102 or placebo for 12 weeks indicate the trial did
not meet its primary efficacy endpoint.

"We are understandably disappointed with the results of this trial; however,
our second Phase 2b trial known as DIGEST is ongoing. In DIGEST we are
evaluating a 10 mg dose of TZP-102 administered three times daily before
meals, rather than once daily as in the trial just completed. We anticipate
announcing top line results for DIGEST in the first half of 2013," said Vipin
K. Garg, PhD, President and Chief Executive Officer of Tranzyme.

The primary efficacy endpoint of the trial was the change from baseline in the
Gastroparesis Symptom Daily Diary (GSDD) composite score during the final two
weeks of a 12-week treatment period. The GSDD composite score reflects the
mean severity of the four principal symptoms of gastroparesis: nausea, early
satiety, bloating and upper abdominal pain. During the two-week pre-treatment
period, the mean baseline GSDD score across all treatment groups was 3.56.
Patients who received either placebo or once-daily dosing of TZP-102 for 12
weeks demonstrated a reduction in the severity of their symptoms, and thus a
reduction in their GSDD scores of -1.46, -1.70 and -1.43 for placebo, 10 mg of
TZP-102 and 20 mg of TZP-102, respectively. Neither the 10 mg dose group nor
the 20 mg dose group of TZP-102 reached statistical significance versus
placebo. Both doses were well-tolerated.

Conference Call Details

Tranzyme will host a conference call today at 8:00 am ET. To participate in
the live call, please dial (877) 670-9784 (U.S. and Canada) or (970) 315-0430
(international), five to ten minutes prior to the start of the call. A live
audio webcast will also be available in the "Investors" section of the
Tranzyme Pharma website, www.tranzyme.com.

A replay of the conference call will be available from today at 11:00 am ET
through November 21, 2012. Investors may listen to the replay by dialing (855)
859-2056 (U.S. and Canada) or (404) 537-3406 (international), with the
conference id 68345812. The webcast will also be archived for on-demand
listening for 30 days at www.tranzyme.com.

TZP-102 Phase 2b Study Design

Two hundred and one (201) patients with type 1 or type 2 diabetes and a
confirmed diagnosis of gastroparesis, documented by the presence of both
chronic symptoms and delayed gastric emptying, were enrolled in a Phase 2b,
double-blind, placebo-controlled, parallel group study in the U.S. and Europe
designed to evaluate the safety and efficacy of TZP-102. Patients were
randomly assigned to receive placebo or one of two dose levels of TZP-102 (10
or 20 mg) given once daily for a treatment period of 12 weeks.

About TZP-102

TZP-102 is an orally-administered ghrelin agonist with highly-differentiated
"first-in-class" potential for the treatment of chronic gastrointestinal
dysmotility disorders such as gastroparesis, functional dyspepsia and
refractory GERD. Ghrelin is a hormone produced mainly by cells of the stomach
which has a highly potent and direct role in stimulating GI motility. TZP-102,
discovered by Tranzyme using its proprietary macrocyclic chemistry technology
(MATCH™), targets the same receptor as the ghrelin hormone. Tranzyme is
currently evaluating the safety and efficacy of TZP-102 in diabetic patients
with gastroparesis. Gastroparesis is a debilitating, chronic condition that
has a significant impact on patients' lives and for which there are limited
treatment options.In recognition of the critical unmet need, the FDA granted
TZP-102 a Fast Track designation for the treatment of gastroparesis in
diabetic patients.

About Gastroparesis

Gastroparesis (paralysis of the stomach) is a serious, debilitating condition
that affects approximately 4% of the general population and up to 12% of
patients with diabetes. It is a progressive disorder characterized by
persistent nausea, vomiting, dehydration and difficulty digesting.
Gastroparesis results in complications with diabetic medicine, making it
difficult for patients to control nutritional and blood glucose levels.
Currently, there are no safe and effective treatments for gastroparesis.
Earlier prescription medications for this indication were withdrawn from the
market or must carry a "black box" warning due to serious side effects.

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing novel, mechanism-based
therapeutics for the treatment of upper gastrointestinal (GI) motility
disorders. While approximately 40% of people in the U.S. are affected by these
persistent and recurring conditions, which disrupt the normal movement of food
throughout the GI tract, there are a limited number of safe and effective
treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for
treating the symptoms associated with chronic upper GI motility disorders.
Enrollment is ongoing in DIGEST, a second Phase 2b trial evaluating TZP-102
given prior to meals in diabetic patients with gastroparesis. Top-line data
for this study are expected in the first half of 2013. By leveraging its
proprietary drug discovery technology, MATCH™, Tranzyme is committed to
pursuing first-in-class medicines to address areas of significant unmet
medical needs.

Further information about Tranzyme Pharma can be found on the Company's web
site at www.tranzyme.com.

Forward-Looking Statements

Statements in this press release may include statements which are not
historical facts and are considered forward-looking within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities Exchange
Act, which are usually identified by the use of words such as "anticipates,"
"believes," "estimates," "expects," "intends," "may," "plans," "projects,"
"seeks," "should," "will," and variations of such words or similar
expressions. We intend these forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange Act and are
making this statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current views about
our plans, intentions, expectations, strategies and prospects, including the
timing of the availability of data from our clinical trial of TZP-102, which
are based on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those described in the
forward-looking statements and will be affected by a variety of risks and
factors that are beyond our control including, without limitation, risks
related to enrollment and successful completion of our trials, risk of
unforeseen side effects, risks related to our collaborations and risks related
to regulatory approval of new drug candidates. Further information on these
and other factors that could affect the company's financial results is
contained in our public filings with the Securities and Exchange Commission
(SEC) from time to time, including our Form 10-Q for the quarter ended
September 30, 2012 which was filed with the SEC on November 9, 2012, and
subsequent filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. We assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com

         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com